IFNA13/Interferon alpha 1/IFNA1 Drug Discovery Landscape & Assay Solutions
- By admin
- 30 Jul 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Antiviral, and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IFNA13/Interferon alpha 1/IFNA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IFNA1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Folding). |
View IFNA1 Products |
| Gene Delivery | IFNA1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IFNA1 Products |
| Benchmark Ab | Anti-IFNA1 (Sequence of Benchmark Therapeutic) Recombinant positive control. |
View IFNA1 Products |
| Validator | IFNA1 siRNA Set For knockdown verification. |
View IFNA1 Products |
| Related Target A | IFNAR1 Primary receptor for Type I Interferons. Crucial for affinity attenuation assays. |
View IFNAR1 Products |
| Related Target B | IFNAR2 Co-receptor required for functional ternary complex formation. |
View IFNAR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex SPR Validation | Human/Mouse/Cyno ortholog receptor proteins available with >95% purity and strictly sequence-verified ECDs. |
| Subfamily Cross-Reactivity Screening | Broad IFNA homolog panel proteins strictly verified by mass spec and theoretical MW. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives in Endogenous Assays | Validatable siRNA included for strict specificity checks in cell models. |
Live IFNA13/Interferon alpha 1/IFNA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IFNA1 therapeutics is intensifying, with major players shifting focus from traditional un-targeted recombinant interferons to precision-targeted immunocytokines and neutralizing antibodies. Historically utilized for broad antiviral responses and systemic oncology treatment, first-generation therapies were limited by severe systemic toxicities (e.g., flu-like syndromes, myelosuppression). As these historical therapies iterate in the clinic, the next wave of R&D is heavily targeting attenuated IFNA variants fused to tumor-targeting antibodies, and highly specific receptor-blocking biologics for autoimmune conditions like Systemic Lupus Erythematosus (SLE).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Immunocytokine (Antibody-Cytokine) | Roche, Philogen, Teva | Solid Tumors (TME Targeting) | Receptor Binding Assay (Need high-purity IFNAR1/2 ECD-Fc) |
| Neutralizing mAb | AstraZeneca, Biogen | SLE, Autoimmune Diseases | Cross-Reactivity Assay (Need diverse IFNA subtype panel) |
| Targeted Nanoparticles / RNAi | Alnylam, Arbutus | Chronic Hepatitis B (HBV) | Target Knockdown Verification (Need verified siRNA/Controls) |